Therapeutics/Diagnostics News

Patients with moderate to severe ulcerative colitis achieved critical clinical, endoscopic and histological outcomes on maintenance doses of upadacitinib compared with placebo, with no new safety risks reported, according to study results.

The FDA granted 510(k) clearance to Limaca Medical’s Precision GI endoscopic ultrasound biopsy device, following breakthrough device designation in May 2022, according to a company press release.

Fecal immunochemical test-based screening was effective in detecting early-stage colorectal cancer at first and repeat screenings, with higher FIT cutoff levels having little effect on stage distribution, data showed.

Colonoscopies performed with artificial intelligence did not improve detection of advanced colorectal neoplasias, although there was enhanced detection of nonpolypoid and smaller lesions, according to data.

Although artificial intelligence-assisted colonoscopy significantly increased detection of adenomas, it also resulted in higher removal rates of non-neoplastic polyps, according to researchers.

A nationwide survey of nearly 89,000 individuals estimated the prevalence of Rome IV irritable bowel syndrome in the U.S. to be 6.1% compared with 4.7% to 5.3% in previous reports, according to a cross-sectional study in Gastroenterology.

All patients with moderate to severe ulcerative colitis in the tofacitinib OCTAVE UC clinical program who underwent colectomy had prior tumor necrosis factor inhibitor failure and most had additional risk factors, according to analysis.

Concomitant use of 5-aminosalicylic acid did not affect the overall safety and efficacy of IV or subcutaneous vedolizumab in patients with inflammatory bowel disease, according to a post hoc analysis in the Journal of Crohn’s and Colitis.

In response to safety concerns surrounding sedation for patients prescribed glucagon-like peptide-1 receptor agonists, the AGA, AASLD, ACG, ASGE and NASPGHAN encourage gastroenterologists to follow “best practices” for endoscopy procedures.

An FDA-approved oral fecal microbiota therapeutic reduces the risk for recurrent Clostridioides difficile infection in high-risk patients compared with placebo, regardless of demographics or baseline risk factors, researchers reported.